Heat, oxidation and exposure to aldehydes create reactive carbonyl groups on proteins, targeting antigens to scavenger receptors. Formaldehyde is widely used in making vaccines, but has been associated with atypical enhanced disease during subsequent infection with paramyxoviruses. We show that carbonyl groups on formaldehyde-treated vaccine antigens boost T helper type 2 (T H 2) responses and enhance respiratory syncytial virus (RSV) disease in mice, an effect partially reversible by chemical reduction of carbonyl groups.
Formaldehyde is widely used in the manufacture of many safe commercial vaccines 1 , but formaldehyde-inactivated RSV and measles vaccines caused disastrous worsening of disease during subsequent natural infection 2 . This phenomenon is reproducible in many animal models, and is characterized by poorly neutralizing antibody 3 , enhanced interleukin (IL)-4, IL-5 and IL-13 responses and tissue eosinophilia 2, 4 . Notably, whereas vaccine-induced antibody can lead to immune complex deposition and contribute to augmented disease 5 , passive immunoglobulin administration prevents lower respiratory tract disease in infants without disease enhancement 6 .
Aldehydes are found in polluted air and cigarette smoke, and are used in the manufacture of textiles, paper and resins; occupational hypersensitivity is common 7 . They are generated in vivo during oxidative stress in atheromatous plaques 8 , in diabetes 8 , alcoholic liver disease 9 , renal failure and in old age during which oxidized proteins, lipids and sugars accumulate 8 . In certain cases, they have potent antimicrobial and detoxifying effects, generating reactive carbonyl groups through intermediate structures on specific amino side chains that form Schiff base adducts 10,11 which react with amino groups of other proteins. Excessive protein carbonylation is found in the lungs of smokers 12 , and the presence of carbonyl groups on macromolecules is detected by scavenger receptors on phagocytic cells 13 , causing uptake and degradation of antigens and enhanced immune priming 9, 14 .
Although glycoaldehyde is known to generate carbonyl groups 10, 15 , similar effects of formaldehyde have not been described. Using a colorimetric 2,4-dinitrophenol hydrazine (DNP) assay to detect carbonyls, we found formaldehyde treatment of ovalbumin (OVA) increased carbonyl content from 131 ± 80 mM/M to 1,440 ± 330 mM/M; reduction with NaBH 3 CN reduced carbonyl content to 210 ± 100 mM/ M (P ¼ 0.02). We propose that this reaction occurs through a Schiff base intermediate (Supplementary Fig. 1 and Supplementary Methods online). Glycoaldehyde-OVA contained multimers that remained despite reductive treatment, whereas formaldehyde induced minimal evidence of multimerization under similar conditions ( Supplementary Fig. 1 online) , suggesting that generation of carbonyl groups rather than protein crosslinking may be responsible for the observed effects.
Injecting OVA subcutaneously into BALB/c mice elicited no antibody response unless given with Freund complete adjuvant (FCA), when strong IgG1 and IgG2a responses were seen. Formaldehyde (FA)-OVA induced a weak but significant IgG1 response without FCA (P o 0.05), but none if FA-OVA underwent reductive treatment with NaBH 3 CN (Fig. 1a,b) ; glycoaldehyde (GA)-OVA showed similar effects ( Supplementary Fig. 1 ). Vaccination of BALB/c mice with FCA-OVA induced interferon (IFN)-g production by spleen cells, absent after FA-OVA vaccination (Fig. 1c) . In contrast, FA-OVA vaccination induced marked IL-5 production, prevented by NaBH 3 CN reduction (Fig. 1d) .
Using the procedure to make 'lot 100' vaccine for human trials, we found that formaldehyde-inactivated RSV (FA-RSV) contained abundant carbonyl groups that could be largely eliminated by reduction with NaBH 3 CN (Supplementary Fig. 1 ). C57BL/6 mice were relatively resistant to infection, but BALB/c mice infected intranasally with human RSV A2, after immunization with FA-RSV, showed a reduction in viral load from 100,000 copies to 100 ( Supplementary Fig. 2 online), but with increased disease and weight loss (Fig. 1e) , lung eosinophilia ( Fig. 1f) and IL-5 production by bronchoalveolar lavage cells (Fig. 1g,h ). Prior chemical reduction reversed all of these effects, except for the effect on viral load ( Supplementary Fig. 2 ). Similar results were obtained with another RSV-sensitive mouse strain, C3H, subsequent to FA-RSV immunization followed by RSV A2 infection (Fig. 2a-c) . Furthermore, immunization of BALB/c mice with glycolaldehyde-inactivated RSV (GA-RSV) also led to weight loss (Fig. 2d), lung eosinophilia (Fig. 2e) and high IL-5 production (Fig. 2f) , all decreased by prior reduction. FA-RSV-vaccinated mice showed strong virus-specific IgG1 responses, switched to IgG2a by reduction ( Supplementary Fig. 3 online) . Normal mouse serum showed no RSV neutralization, and sera from mice twice infected with RSV intranasally showed 50% neutralization at 1:640. Heatinactivated (HI)-RSV immunization gave 50% neutralization at 1:121, whereas FA-RSV or chemically reduced FA-RSV (FA-RSV-Re) sera did not neutralize at 1:20 (data not shown).
Therefore, the presence of reactive carbonyl groups favors a T H 2 response, consistent with reports of boosted IgG1 (ref. 14) and attenuated IgG2a responses 9 to aldehyde-treated proteins. We suggest that this results from phagocytosis of aldehyde-treated proteins and lipoproteins by macrophages via scavenger receptors 13 . Reasons to think that this is a specific effect of carbonyl recognition include that: (i) carbonyl groups generated on glycoproteins by other means (for example, oxidation) also enhance immunogenicity 14 ; (ii) carbonyl groups alter responses to the treated antigen, but not to coadministered unmodified antigen 14 ; (iii) reductive elimination of carbonyl groups on proteins reduces uptake of the modified protein by macrophage scavenger receptors 13 ; and (iv) monomeric carbonylprotein adducts are as immunogenic as the crosslinked species 14 .
Our studies highlight the importance of carbonyl groups in formaldehyde-treated vaccines, and suggest that this may in part explain the adverse effects of formaldehyde vaccines in measles and RSV infections. Many current vaccines are inactivated or detoxified with formalin, and carbonyl groups may enhance immunogenicity and efficacy without necessarily causing adverse effects. Other factors must clearly be important, such as the chemical and structural nature of the antigen to which carbonyls are added, antigen-specific structural alterations after addition of carbonyls, and the protective and deleterious immune mechanisms in a given infection. However, the avoidance of formalin in manufacture, the use of alternative inactivating agents that do not induce carbonyl groups (for example, b-propiolactone; data not shown) or the use of reducing agents to eliminate carbonyls may have marked effects on the immune profile induced by vaccines. Although our findings highlight adverse effects, formalin-inactivated vaccines have been given to millions of people worldwide with excellent protective results. Our data show, however, that the induction of carbonyl groups on vaccine antigens by formalin treatment may profoundly affect immunogenicity, changing the balance between protective and deleterious immune responses. 
